I-Mab Starts China Trial of Ulcerative Colitis Treatment

23:31 EDT 12 Oct 2018 | ChinaBio Today

I-Mab Biopharma of Shanghai reported the first patient has been dosed in a China Phase II trial of TJ301 in patients with ulcerative colitis. I-Mab in-licensed China rights to the candidate from Switzerland's Ferring in late 2016. TJ301 is a selective IL-6 blocker that allows IL-6 to continue responding to infections, while it moderates the UC immune response. Because of its selective blocking mechanism, TJ301 is expected to show a better safety profile than its competitors. I-Mab has rights to the candidate in greater China and Korea. More details....

Share this with colleagues:

Original Article: I-Mab Starts China Trial of Ulcerative Colitis Treatment


More From BioPortfolio on "I-Mab Starts China Trial of Ulcerative Colitis Treatment"

Quick Search


Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...